Orbimed Advisors LLC Harpoon Therapeutics, Inc. Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.65 - $1.37 $581,930 - $1.23 Million	-895,278 Reduced 59.04%	621,218 $459,000
Q4 2022 Feb 14, 2023	SELL	$0.6 - $1.41 $905,647 - $2.13 Million	-1,509,412 Reduced 49.88%	1,516,496 $1.11 Million
Q3 2022 Nov 14, 2022	SELL	$0.94 - $2.56 $12,784 - $34,816	-13,600 Reduced 0.45%	3,025,908 $2.94 Million
Q1 2022 May 16, 2022	BUY	$3.54 - $8.08 $481,440 - $1.1 Million	136,000 Added 4.68%	3,039,508 $15.1 Million
Q4 2021 Feb 14, 2022	BUY	$5.69 - $7.83 $1.66 Million - $2.29 Million	292,200 Added 11.19%	2,903,508 $21.9 Million
Q2 2021 Aug 16, 2021	BUY	$13.81 - $23.25 $4.5 Million - $7.57 Million	325,604 Added 14.25%	2,611,308 $36.2 Million
Q1 2021 May 17, 2021	BUY	$17.65 - $24.16 $7.94 Million - $10.9 Million	450,000 Added 24.51%	2,285,704 $47.8 Million
Q2 2020 Aug 14, 2020	SELL	$11.11 - $24.72 $6.78 Million - $15.1 Million	-610,705 Reduced 24.96%	1,835,704 $30.5 Million
Q1 2019 May 15, 2019	BUY	$9.47 - $17.01 $23.2 Million - $41.6 Million	2,446,409 New	2,446,409 $23.2 Million

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.